Navigation Links
Inovio Pharmaceuticals' Synthetic Vaccine for Cancer Recognized as Most Promising Research at Global Vaccine Congress
Date:10/5/2011

pable of killing targets in an antigen-specific manner -- a finding that may prove crucial to the success of an effective therapy for HPV-related disease.

Dr. J. Joseph Kim, president and CEO, said, "We greatly appreciate this recognition of Inovio's leadership and innovation in advancing the development of novel vaccines and analytical methods to assess vaccine effects. Our SynCon® vaccines administered with our proprietary electroporation delivery systems have generated best-in-class immune responses in our Phase I clinical trials for cervical dysplasia and HIV. The demonstration of antigen-specific CTL activity induced by Inovio's synthetic vaccines delivered by its proprietary CELLECTRA® electroporation system speaks well for our synthetic vaccine platform in general and in particular for our cancer vaccine programs."

Inovio has active therapeutic vaccine programs for HPV 16 and 18 associated cervical dysplasia/cancer (Phase II), chronic and acute myeloid leukemia (Phase II), prostate cancer (pre-clinical), hepatitis C virus (Phase II), and HIV (Phase I).

About Inovio Pharmaceuticals, Inc.

Inovio is developing its revolutionary synthetic consensus immunogen technologies to extend the profound medical benefits of the 20th century's immune-system-stimulating vaccines by preventing and treating today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery method, have been shown in humans to be safe and generate best-in-class immune responses. Inovio's clinical programs include Phase II studies for cervical dysplasia/cancer, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merc
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release third quarter 2014 financial results on Wednesday, ... The Company,s management will hold a conference call ... 2014, which is 8:30 p.m., Beijing Time on November ...
(Date:10/30/2014)... , La fórmula de ... adquirir tolerancia a la proteína de leche de ... la leche de la vaca (APLV) es la principal alergia ... la APLV se trataba eliminando las proteínas lácteas ... es posible adquirir tolerancia oral en un número ...
(Date:10/30/2014)... 2014 The global newborn screening market ... technology, product, and geography. The mass spectrometry market ... in the newborn screening market by technology, during ... to various nations opting for expanded newborn screening. ... for expanded newborn screening. Furthermore, various conferences and ...
Breaking Medicine Technology:China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3
... 11 El Camino Hospital, the hospital of Silicon ... da Vinci® Si HD Surgical Systems. Physicians performed more ... expect the number to increase in 2010 as more ... for more minimally invasive procedures. The new systems feature ...
... BROOMFIELD, Colo., Nov. 11 Accera, Inc., a biotechnology company ... that it will present at Lazard Capital Markets 6th Annual ... in New York. , Steve Orndorff, Ph.D., founder, president ... an update on Axona (TM) on Tuesday, November 17 ...
Cached Medicine Technology:El Camino Hospital Expands Robotic Surgery Program 2El Camino Hospital Expands Robotic Surgery Program 3El Camino Hospital Expands Robotic Surgery Program 4Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference 2
(Date:10/30/2014)... 2014 USARAD Holdings Inc ... and specialty telemedicine solutions provider, including SecondOpinions.com ... existing teleradiology services at Mission Bend ER, it ... telemedicine services, to the state-of-the-art, 24/7, freestanding ER ... of this innovative partnership, there will be many ...
(Date:10/30/2014)... WA (PRWEB) October 30, 2014 Sound Telecom, ... decision infographic that will assist people any time they wonder, ... discover the right answer by leading them through a series ... resolution to their initial query. , There are many considerations ... not to use an answering service . This decision ...
(Date:10/30/2014)... News) -- Many U.S. colleges have indoor tanning ... increases the risk for skin cancer, researchers report. ... white women, so colleges should adopt tanning-free policies, ... "Public health efforts are needed to raise ... harms that indoor tanning poses to young adults ...
(Date:10/30/2014)... 29, 2014) – A new standard of care for ... following a multi-year study published in the latest edition ... , The research, led by John Wagner, Jr., M.D., ... at the University of Minnesota and a researcher in ... in children with acute leukemia and myelodysplastic syndrome who ...
(Date:10/28/2014)... and outer body and organ surfaces in the human ... in the inner ear," said Moritz Gegg. Cilia – ... are precisely positioned on many of these epithelial cells. ... coordinated so precisely that for example mucus can be ... from sensory inner ear hair cells," added Heiko Lickert. ...
Breaking Medicine News(10 mins):Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:New insights into the development of ciliopathies 2
... the seventh leading cause of cancer death worldwide, the ... group and gender. Esophageal cancer is thought to be ... with the host genome. Researchers have long been seeking ... conducted on gene-environment interaction and gene polymorphisms for esophageal ...
... intellectual property laws devalue the "repurposing" of existing ... life-saving treatments, a Portland researcher contends. , S. ... behavioral neuroscience in the Oregon Health & Science ... Affairs Medical Center, writes in a letter appearing ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today ... Pharmaceuticals GmbH (Merz) for sales,by Merz and its ... severe Alzheimer,s disease for the quarter ended June ... royalty payments compared to,the same quarter last year, ...
... Oct. 31 MAP,Pharmaceuticals, Inc. (Nasdaq: ... the initiation of a Phase 2a clinical ... asthma and chronic obstructive,pulmonary disease (COPD). ... and a long-acting,beta2-agonist delivered to the respiratory ...
... and Offshore Healthcare Expertise and ... Service Delivery Capabilities EL SEGUNDO, Calif. ... CSC ) and,First Consulting Group, Inc. (Nasdaq: FCGI ) today ... through which CSC will acquire,First Consulting Group (FCG) in an all-cash ...
... EDMONTON, Oct. 31 /PRNewswire-FirstCall/ - BioMS Medical Corp ... multiple sclerosis (MS), today,announced that Mr. Kevin Giese, ... Rodman and Renshaw 9th Annual Healthcare Conference in ... 3:20 pm (Local Time), WHERE: New York ...
Cached Medicine News:Health News:ADH2 and ALDH2 are associated with esophageal cancer 2Health News:Old drugs need 'repurposing' for new uses, physician says 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 2Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 3Health News:MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma 4Health News:CSC Agrees to Acquire First Consulting Group 2Health News:CSC Agrees to Acquire First Consulting Group 3Health News:CSC Agrees to Acquire First Consulting Group 4Health News:CSC Agrees to Acquire First Consulting Group 5Health News:BioMS Medical to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Inquire...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
Medicine Products: